Measuring the Proteins That Matter Most with SomaSeq Discovery

This sequencing-based approach fills an important gap in the proteomics toolbox. While mass spectrometry remains the leading technology for unbiased protein discovery, isoform characterization, and post-translational modification analysis, many researchers are ultimately interested in a different question: how do known, biologically relevant proteins change across hundreds or thousands of samples? SomaSeq Discovery is optimized for exactly that use case, delivering the sensitivity, reproducibility, and scalability required for large-cohort studies.

Rather than competing with mass spectrometry, SomaSeq Discovery is often most powerful when used alongside it. Mass spectrometry can identify novel biological signals and generate new hypotheses, while SomaSeq Discovery can rapidly evaluate those signals across large collections of samples. As projects move from discovery into validation, biomarker assessment, or longitudinal analysis, the ability to generate standardized protein measurements at scale becomes increasingly valuable.

The platform is also a natural fit for modern multiomics research. Protein abundance reflects biological activity that cannot always be predicted from DNA or RNA alone. Integrating proteomic data with genomic and transcriptomic datasets can help researchers connect genetic variation and gene expression to downstream molecular phenotypes, providing a more complete view of disease mechanisms and pathway activity.

At SeqCenter, SomaSeq Discovery is available for human serum samples and is sequenced on a dedicated Illumina NovaSeq X Plus flow cell. For researchers studying cancer, immunology, inflammation, neurology, metabolism, and other complex diseases, SomaSeq Discovery provides a practical way to add large-scale proteomic profiling to an existing NGS-driven research program without requiring specialized mass spectrometry workflows.